KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for West Pharmaceutical Services (WST) over the last 17 years, with Q3 2025 value amounting to $4.1 billion.

  • West Pharmaceutical Services' Liabilities and Shareholders Equity rose 1171.94% to $4.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $15.3 billion, marking a year-over-year increase of 495.95%. This contributed to the annual value of $3.6 billion for FY2024, which is 485.96% down from last year.
  • Latest data reveals that West Pharmaceutical Services reported Liabilities and Shareholders Equity of $4.1 billion as of Q3 2025, which was up 1171.94% from $4.0 billion recorded in Q2 2025.
  • In the past 5 years, West Pharmaceutical Services' Liabilities and Shareholders Equity ranged from a high of $4.1 billion in Q3 2025 and a low of $2.7 billion during Q1 2021
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $3.6 billion (2022), whereas its average is $3.5 billion.
  • In the last 5 years, West Pharmaceutical Services' Liabilities and Shareholders Equity skyrocketed by 2262.26% in 2021 and then tumbled by 491.06% in 2024.
  • Quarter analysis of 5 years shows West Pharmaceutical Services' Liabilities and Shareholders Equity stood at $3.3 billion in 2021, then rose by 9.14% to $3.6 billion in 2022, then grew by 5.88% to $3.8 billion in 2023, then fell by 4.86% to $3.6 billion in 2024, then rose by 12.69% to $4.1 billion in 2025.
  • Its Liabilities and Shareholders Equity was $4.1 billion in Q3 2025, compared to $4.0 billion in Q2 2025 and $3.6 billion in Q1 2025.